Walleye Capital LLC Has $2.43 Million Stock Holdings in Aquestive Therapeutics, Inc. $AQST

Walleye Capital LLC boosted its holdings in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 103.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 584,977 shares of the company’s stock after purchasing an additional 297,166 shares during the period. Walleye Capital LLC’s holdings in Aquestive Therapeutics were worth $2,428,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in AQST. Victory Capital Management Inc. grew its stake in shares of Aquestive Therapeutics by 17.0% in the 3rd quarter. Victory Capital Management Inc. now owns 12,794 shares of the company’s stock valued at $72,000 after purchasing an additional 1,862 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Aquestive Therapeutics by 6.0% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company’s stock worth $156,000 after buying an additional 2,649 shares during the period. Informed Momentum Co LLC boosted its stake in Aquestive Therapeutics by 1.8% in the 4th quarter. Informed Momentum Co LLC now owns 155,053 shares of the company’s stock valued at $1,002,000 after buying an additional 2,721 shares in the last quarter. Sugar Maple Asset Management LLC boosted its stake in Aquestive Therapeutics by 5.9% in the 1st quarter. Sugar Maple Asset Management LLC now owns 58,060 shares of the company’s stock valued at $241,000 after buying an additional 3,210 shares in the last quarter. Finally, Stifel Financial Corp grew its position in Aquestive Therapeutics by 0.9% in the fourth quarter. Stifel Financial Corp now owns 369,728 shares of the company’s stock valued at $2,388,000 after acquiring an additional 3,300 shares during the period. 32.45% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Aquestive Therapeutics

In other Aquestive Therapeutics news, CEO Daniel Barber sold 8,257 shares of the business’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $4.29, for a total value of $35,422.53. Following the transaction, the chief executive officer owned 660,574 shares of the company’s stock, valued at approximately $2,833,862.46. The trade was a 1.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julie Krop sold 25,000 shares of the stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $5.02, for a total value of $125,500.00. Following the sale, the director owned 25,000 shares in the company, valued at $125,500. The trade was a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.81% of the company’s stock.

Aquestive Therapeutics Trading Down 4.3%

NASDAQ:AQST opened at $3.77 on Friday. Aquestive Therapeutics, Inc. has a 1 year low of $2.93 and a 1 year high of $7.55. The firm has a 50 day moving average of $4.19 and a 200-day moving average of $4.11. The stock has a market capitalization of $473.02 million, a P/E ratio of -6.18 and a beta of 1.45.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.07. The business had revenue of $14.45 million for the quarter, compared to the consensus estimate of $10.90 million. As a group, analysts forecast that Aquestive Therapeutics, Inc. will post -0.41 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Wall Street Zen upgraded Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Oppenheimer started coverage on shares of Aquestive Therapeutics in a research note on Friday, April 24th. They issued an “outperform” rating and a $8.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Friday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $8.50.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.